A controlled trial of azathioprine in behçet's syndrome

New England Journal of Medicine

Volumn 322, Issue 5, 1990, Pages 281-285

  Yazici, Hasan ^a   Pazarli, Halit ^a   Barnes, Colin G ^b   Tüzün, Yalçin ^a   Özyazgan, Yilmaz ^a   Silman, Alan ^b   Serdaroğlu, Server ^a   Oğuz, Velieddin ^a   Yurdakul, Sebahattin ^a   Lovatt, George E ^c   Yazici, Berrin ^a   Somani, Shenaz ^b   Müftüoğlu, Asuman ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AZATHIOPRINE; BEHCET SYNDROME; DOUBLE-BLIND METHOD; EYE DISEASES; HUMAN; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; RETINITIS; SUPPORT, NON-U.S. GOV'T; SUPPURATION; UVEITIS; VISUAL ACUITY;

EID: 0025014790     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199002013220501     Document Type: Article

References (14)

1. Shimizu T. Ehrlich GE, Inaba G, Hayashi K. Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979; 8: 223–60.
2. Behçet's disease. Lancet 1989; 1: 761–2.
3. Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Yalçin B, Müftüoğlu A. Behçet's disease as seen in Turkey. Haematologica (Pavia) 1980; 65: 381–3.
4. Rosselet F, Saudan Y, Zenklusen G. Les effets de l'azathioprine (“Imuran”) dans la maladie de Behçet: premiers résultats thérapeutiques. Ophthalmologica (Basel) 1968; 156: 218–26.
5. Lessof MH, Jeffreys DB, Lehner T, Mattock M, Sanders MD. Corticosteroids and azathioprine: their use in Behćet's syndrome. In: Lehner T, Barnes CG, eds. Behćet's syndrome: clinical and immunological features. London: Academic Press, 1979:218–26.
6. O'Duffy JD. Suggested criteria for diagnosis of Behçet's disease (BD). J Rheumatol 1974; 1: Suppl 1: 18. abstract.
7. O'Duffy. Criteres proposes pour le diagnostic de la maladie de Behçet et notes therapeutiques. Rev Med 1974 b; 36: 237–9.
8. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39.
9. Lehner T. Autoimmunity in oral diseases, with special reference to recurrent oral ulceration. Proc R Soc Med 1968; 61: 515–24.
10. O'Duffy JD. Treatment of Behçet's disease with chlorambucil. In: Inaba G. ed. Behçet's disease: pathogenetic mechanism and clinical features: proceedings of the International Conference on Behçet's Disease, held October 23–24, 1981. Tokyo: University of Tokyo Press, 1982:479–85.
11. O'Duffy JD, Bowles CA, O'Fallon WM. The immunosuppressive treatment of Behçet's disease with emphasis on chlorambucil. In: Lehner T, Barnes CG, eds. Recent advances in Behçet's disease. International congress and symposium series no. 103. London: Royal Society of Medicine, 1986:301–6.
12. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 12: 988–92.
13. Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783–9.
14. Serdaroğlu P, Yazici H. Özdemir C, Yurdakul S, Bahar S, Aktin E. Neurological involvement in Behçet's syndrome: a prospective study. Arch Neurol 1989; 46: 265–9.